{
    "nct_id": "NCT03600883",
    "official_title": "A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)",
    "inclusion_criteria": "* Men or women greater than or equal to 18 years old.\n* Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing.\n\nExclusion Criteria\n\n* Active brain metastases from non-brain tumors.\n* Myocardial infarction within 6 months of study day 1.\n* Gastrointestinal (GI) tract disease causing the inability to take oral medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}